Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of the mRNA mpox vaccine candidate BNT166a in Africa
PACTR202601475113911Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised trial of BNT166 in mpox, sponsored by BioNTech SE. Started Feb 2026; status: recruiting.
02
Drugs
BNT166
03
Conditions
mpox
Beyond the preview
Go deeper on PACTR202601475113911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202601475113911.